How Has The Central Nervous System Biomarkers Market Size Evolved In Recent Years?
The central nervous system biomarkers market has seen considerable growth due to a variety of factors.
•The market for central nervous system biomarkers has expanded swiftly over the past few years. The market is projected to expand from $5.58 billion in 2024 to $6.15 billion in 2025, with a compound annual growth rate (CAGR) of 10.2%.
Factors including increased concern about neurological disorders, high incidences of central nervous system diseases, elevated demand for superior diagnostics and treatments, advancements in healthcare facilities, and the growing elderly population contributed to the growth during the historic period.
What Is The Projected Growth Of The Central Nervous System Biomarkers Market?
The central nervous system biomarkers market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for central nervous system biomarkers is predicted to witness substantial expansion in the upcoming years, surging to $9 billion by 2029 with a compound annual growth rate (CAGR) of 10.0%.
The anticipated growth during the projection period can be credited to the intensifying cases of neurological disorders, escalating demand for person-specific medicine, expanding aged-population, heightened focus on preliminary diagnoses, and the increasing necessity for non-intrusive diagnostic tools. Major developments expected to shape the market during this forecast period encompass novel technological advancements, strategic partnerships among biotech companies, pharmaceutical establishments, and other key players, progress in the research on cerebrospinal fluid (csf) and blood-based biomarkers, and application of AI and machine learning algorithms.
What Are The Primary Growth Drivers In The Central Nervous System Biomarkers Market?
The surge in neurological diseases is anticipated to boost the expansion of the central nervous system biomarker market in the future. Neurological diseases encapsulate a myriad of conditions affecting the brain, spinal cord, and nerves throughout the body and can be caused by genetics, infections, autoimmune reactions, degenerative events, tumors, vascular problems, and traumatic injuries. Central nervous system (CNS) biomarkers are crucial in diagnosing these disorders, gauging the risk or prognosis of the illness, evaluating disease stage, and monitoring treatment efficacy. They are pivotal in deciphering the nature of these diseases and the possibility of their treatment. For example, in April 2023, the Centers for Disease Control and Prevention, a government agency in the US, found that around 6.7 million Americans aged 65 and above were affected by Alzheimer's disease. This figure is projected to almost triple to 14 million by 2060. Further, the prevalence of the disease doubles every five years post the age of 65. Consequently, the surge in neurological diseases propels the growth of the central nervous system biomarker market.
What Is The Segmentation Of The Global Central Nervous System Biomarkers Market?
The central nervous system biomarkers market covered in this report is segmented –
1) By Type: Safety Biomarker, Efficacy Biomarker, Validation Biomarker, Other Types
2) By Disease: Multiple Sclerosis, Alzheimer's Disease, Parkinson's Disease, Traumatic Brain Injury, Other Diseases
3) By Application: Drug Discovery And Development, Personalized Medicines, Disease Risk Assessment, Diagnostics, Other Applications
4) By End-Users: Diagnostic Labs, Clinics, Hospitals, Research Centers, Other End-Users
Subsegments:
1) By Safety Biomarker: Toxicity Biomarkers, Adverse Event Biomarkers
2) By Efficacy Biomarker: Pharmacodynamic Biomarkers, Response Biomarkers
3) By Validation Biomarker: Predictive Biomarkers, Prognostic Biomarkers
4) By Other Types: Diagnostic Biomarkers, Biomarkers For Disease Progression
Pre-Book The Central Nervous System Biomarkers Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Central Nervous System Biomarkers Market Landscape?
One significant trend gaining traction in the central nervous system biomarker market is the approval of innovative drugs. Key players in this market are investing their efforts in the creation of groundbreaking drugs and obtaining necessary approvals to reinforce their market standing. For example, in January 2022, Denovo Biopharma LLC, a clinical-stage biopharmaceutical firm from the US, publicized the approval and sanction of their Investigational New Drug (IND) application for DB104 (Liafensine) from the US Food and Drug Administration (FDA), specifically for treating treatment-resistant depression (TRD). This marks the first global CNS clinical trial for TRD that is guided by a biomarker. Moreover, it might assist in recognizing patients who might have a more favorable response to liafensine, thus enabling more personalized treatment options. Liafensine is a unique compound that enhances dopamine and norepinephrine levels in the brain.
Who Are the Key Players in the Central Nervous System Biomarkers Market?
Major companies operating in the central nervous system biomarkers market include:
• F. Hoffmann-La Roche AG
• Novartis AG
• Siemens Healthineers
• Thermo Fisher Scientific Inc
• Abbott Laboratories
• Merck KGaA
• Eurofins Scientific
• Charles River Laboratories International Inc.
• PerkinElmer Inc.
• Bio-Rad Laboratories Inc.
• QIAGEN N.V.
• Axon Neuroscience SE
• Alector Inc.
• Oryzon Genomics S.A.
• Abastar Mdx Inc.
• Banyan Biomarkers Inc.
• Avacta Group PLC
• Geno Technology Inc.
• Anavex Life Sciences Corp.
• Alseres Pharmaceuticals Inc.
• Aposense Ltd.
• Applied Neurosolutions Inc.
• C2N Diagnostics
• Alzheon Inc.
• DiaGenic ASA
• Abiant Inc.
• Avid Radiopharmaceuticals Inc.
• Acumen Pharmaceuticals Inc.
• Cassava Sciences Inc.
• Denali Therapeutics
What are the Regional Insights into the Central Nervous System Biomarkers Market?
North America was the largest region in the central nervous system biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
